FOCUS-Europe ready to cash in on cheap copies of AbbVie biotech drug

U.S. drugmaker AbbVie faces a crunch moment in Europe in mid-October when less-expensive copies of its $18-billion-a-year biologic drug Humira – the world's best-selling prescription medicine – hit the market.